clinical trial · NCT06569680
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
Izidore Lossos, MD·phase2·recruiting·n = 35
Extranodal Marginal Zone LymphomaMosunetuzumab
brief summary
The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer is in stage I-IV. This study will help doctors understand if Mosunetuzumab improves outcomes in people with EMZL and if it is safe to use.
started
Nov 19, 2024
primary completion
Dec 1, 2030
completion
Dec 1, 2030
last updated
Nov 3, 2025
official title
Phase II Trial of Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma (EMZL) (ML44933)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol